Influence of hyperlipidemia and its treatment on outcome in patients with peripheral arterial disease

Daniel Ihnat, Gerlinda Tynan-Cuisiner, Joseph L. Mills

Research output: Contribution to journalReview article

Abstract

Patients with peripheral artery disease (PAD), coronary heart disease, and diabetes mellitus have been shown conclusively to experience a 25% reduction in the rate of cardiovascular death, myocardial infarction, stroke and revascularization procedures by treatment with 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors. Despite these findings, patients with PAD are frequently undertreated with respect to HMG-CoA reductase inhibitors, compared to patients with CHD. In addition, HMG-CoA reductase inhibitors produce numerous pleiotrophic effects that may reduce the incidence of restenosis after revascularization procedures.

Original languageEnglish (US)
Pages (from-to)317-321
Number of pages5
JournalVascular Disease Management
Volume3
Issue number4
StatePublished - Jul 1 2006

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Influence of hyperlipidemia and its treatment on outcome in patients with peripheral arterial disease'. Together they form a unique fingerprint.

  • Cite this